Lead Product(s): Brazikumab
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $63,000.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 05, 2020
As part of the deal, Allergan has agreed to divest brazikumab, an investigational IL-23 inhibitor in development for autoimmune diseases, to AstraZeneca and Zenpep, a treatment for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions, to Nestle.